Journal: Cell Reports Medicine

Article Title: Decoupling HIV-1 antiretroviral drug inhibition from plasma antibody activity to evaluate broadly neutralizing antibody therapeutics and vaccines

doi: 10.1016/j.xcrm.2024.101702

Figure Lengend Snippet: Differential sensitivity of VSV-based pseudoviruses to antibody neutralization (A) Infectivity of VSV pv viruses pseudotyped with full-length (open symbols) or CT-truncated (ΔCT) HIV-1 Env/R peptide-deleted (ΔR) MuLV (closed symbols). Infectivity of virus titrations was measured on TZM-bl cells and recorded as RLUs. Error bars indicate the standard deviation. (B) Sensitivity of MuLV-pseudotyped VSV pv viruses (blue) to ARVs with ARV concentrations as shown in Figure 1 B. IC50 values of two independent experiments in a TZM-bl-based neutralization assay are shown. Error bars indicate the standard deviation. Data for HIV pv -WT (black) from Figure 1 C are depicted for comparison. (C) Neutralization of a 13-virus panel in the context of HIV pv -WT (black), Env ΔCT VSV pv (blue), and Env ΔCT HIV pv -WT (gray) by a panel of 30 bnAbs. Mean IC50 values of two independent experiments are shown. Significance thresholds are adjusted for multiple testing and indicated as follows: ∗ p < 0.05/18, ∗∗ p < 0.01/18, ∗∗∗ p < 0.001/18. (D) Sensitivity of the different pseudoviruses to six low/non-neutralizing mAbs. Mean IC50 values of two independent experiments are shown. Significance thresholds are adjusted on multiple testing and indicated as follows: ∗ p < 0.05/12, ∗∗ p < 0.01/12, ∗∗∗ p < 0.001/12. (E) IC50 comparison of VSV pv -sensitive low/non-neutralizing mAb/virus combinations with HIV pv -WT as depicted in (D). See also Figure S2 and Table S3 .

Article Snippet: A full list of mAb sources is provided in . mAbs 2G12, 4E10, and 447 were obtained from Polymun Scientific GmbH, Austria.

Techniques: Neutralization, Infection, Virus, Standard Deviation, Comparison